<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096668</url>
  </required_header>
  <id_info>
    <org_study_id>SON-8184-1074</org_study_id>
    <nct_id>NCT00096668</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer</brief_title>
  <official_title>A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(R) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) as Initial Treatment of Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <brief_summary>
    <textblock>
      This is an open label study where each patient will receive TOCOSOL(R) Paclitaxel 120mg/m2&#xD;
      every week for first line treatment of metastatic breast cancer. Patients will be followed to&#xD;
      determine the efficacy of treatment (as measured by objective response rate), and the safety&#xD;
      associated with weekly administration of TOCOSOL Paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, non-randomized Phase 2 study of weekly administration of TOCOSOL&#xD;
      Paclitaxel at a dose level, 120mg/m2, known to be tolerated based on Phase 2a studies of this&#xD;
      investigational agent in patients with other histological diagnoses. This study is a fixed&#xD;
      sample size design with no planned early stopping decision. The goals of the study include&#xD;
      the determination of the safety of TOCOSOL Paclitaxel, and the objective response rate,&#xD;
      defined by RECIST criteria as complete responses plus partial responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>After all patients complete treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>After alll patients complete treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TOCOSOL Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TOCOSOL Paclitaxel administered weekly at 120mg/mm2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOCOSOL(R) Paclitaxel</intervention_name>
    <arm_group_label>TOCOSOL Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patient with histologic diagnosis of breast carcinoma&#xD;
&#xD;
          -  Stage IV (M1) disease&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy regimen for treatment of metastatic breast cancer&#xD;
&#xD;
          -  Adult (18 years of age or older) patients&#xD;
&#xD;
          -  Adequate hematologic function (ANC &gt;=1500 cells/mm3 and platelets &gt;100,000/mm3&#xD;
&#xD;
          -  Serum creatinine &lt;=2.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin &lt;=1.5 mg/dL&#xD;
&#xD;
          -  AST/SGOT and ALT/SGPT &lt;=3 times the upper limit of institutional normal values&#xD;
&#xD;
          -  PT and PTT within institutional normal range&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion as defined by RECIST criteria&#xD;
             assessable by radiographic evaluation&#xD;
&#xD;
          -  A signed IRB/Ethics Committee approved Informed Consent&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Fully recovered from any previous surgery&#xD;
&#xD;
          -  A negative pregnancy test prior to study entry if premenopausal&#xD;
&#xD;
          -  Agree not to take Vitamin E supplementation while receiving study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior taxane-containing chemotherapy including Taxol or Taxotere&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  Peripheral neuropathy NCI-CTC grade 2 or greater&#xD;
&#xD;
          -  Wide-field radiation, hormonal therapy or trastuzumab within 4 weeks of first dose of&#xD;
             study drug; cytotoxic chemotherapy within 6 months of first dose of study drug&#xD;
&#xD;
          -  Treatment with an investigational agent within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Patients with a history of carcinomas of primary sites which can not be distinguished&#xD;
             histologically from metastatic breast carcinoma&#xD;
&#xD;
          -  Bone metastasis, effusions, ascites or elevated tumor markers as the only evidence of&#xD;
             metastatic breast carcinoma&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Active bowel obstruction&#xD;
&#xD;
          -  Active, serious infection or other serious medical problems (other than metastatic&#xD;
             breast cancer) likely to impair completion of the study protocol&#xD;
&#xD;
          -  Concurrent therapy with known substrates or inhibitors of the cytochrome P450&#xD;
             isoenzymes CYP2C8 or CYP3A4&#xD;
&#xD;
          -  Concurrent therapy with warfarin or other coumarin derivatives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkhangelsk Regional Oncology Center</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Oncology Clinical Hospital #62</name>
      <address>
        <city>Krasnogorskiy Region</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blokhin Russian Oncology Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semashko Central Clinical Hospital of the Ministry of Transport</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Petersburg Oncology Center</name>
      <address>
        <city>St Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petrov Research Institute of Oncology</name>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Oncology Center</name>
      <address>
        <city>Voronezh</city>
        <zip>3394000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>November 12, 2004</study_first_submitted>
  <study_first_submitted_qc>November 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2004</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Monica Krieger, VP Regulatory Affairs</name_title>
    <organization>OncoGenex Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>TOCOSOL Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

